Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial

[1]  F. Frippiat,et al.  Meropenem: continuous or extended infusion? , 2020, Critical Care.

[2]  J. Carazo,et al.  Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia. , 2019, The Journal of antimicrobial chemotherapy.

[3]  R. Wunderink,et al.  Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future HABP/VABP clinical trials. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Torres,et al.  Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model , 2018, Antimicrobial Agents and Chemotherapy.

[5]  D. Marriott,et al.  Too much of a good thing: a retrospective study of &bgr;-lactam concentration–toxicity relationships , 2017, The Journal of antimicrobial chemotherapy.

[6]  P. Lescuyer,et al.  Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  A. Oliver,et al.  Determining &bgr;-lactam exposure threshold to suppress resistance development in Gram-negative bacteria , 2017, The Journal of antimicrobial chemotherapy.

[8]  D. Paterson,et al.  Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model , 2017, Antimicrobial Agents and Chemotherapy.

[9]  C. Thomson,et al.  Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. , 2016, Annals of the American Thoracic Society.

[10]  R. Bellomo,et al.  Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. , 2016, American journal of respiratory and critical care medicine.

[11]  Peggy Cruse,et al.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Vogeser,et al.  Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study , 2016, Critical Care.

[13]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[14]  R. Bellomo,et al.  A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. , 2015, American journal of respiratory and critical care medicine.

[15]  S. Harbarth,et al.  Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? , 2015, The Journal of antimicrobial chemotherapy.

[16]  Michael N Neely,et al.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. , 2014, The Lancet. Infectious diseases.

[17]  J. Rello,et al.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Mouton,et al.  Exposure to Ceftobiprole Is Associated with Microbiological Eradication and Clinical Cure in Patients with Nosocomial Pneumonia , 2014, Antimicrobial Agents and Chemotherapy.

[19]  M. Weinstein,et al.  Using Higher Doses to Compensate for Tubing Residuals in Extended-Infusion Piperacillin-Tazobactam , 2013, The Annals of pharmacotherapy.

[20]  A. Schumitzky,et al.  Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  F. Barbier,et al.  Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients , 2013, Antimicrobial Agents and Chemotherapy.

[22]  Charlie Strange,et al.  An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. , 2012, American journal of respiratory and critical care medicine.

[23]  Alan Schumitzky,et al.  Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R , 2012, Therapeutic drug monitoring.

[24]  K. Rodvold,et al.  Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid , 2011, Clinical pharmacokinetics.

[25]  A. Oliver,et al.  Meropenem Penetration into Epithelial Lining Fluid in Mice and Humans and Delineation of Exposure Targets , 2011, Antimicrobial Agents and Chemotherapy.

[26]  C. Kirkpatrick,et al.  Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients , 2011 .

[27]  G. Drusano,et al.  Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  P. Tulkens,et al.  Stability of meropenem and doripenem solutions for administration by continuous infusion. , 2010, The Journal of antimicrobial chemotherapy.

[29]  Brian Van Scoy,et al.  The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression , 2010, Antimicrobial Agents and Chemotherapy.

[30]  M. Roberts,et al.  Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. , 2009, The Journal of antimicrobial chemotherapy.

[31]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[32]  J. Roberts,et al.  Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.

[33]  M. Kinzig,et al.  Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia , 2011, Antimicrobial Agents and Chemotherapy.

[34]  D. Nicolau.  Pharmacokinetic and pharmacodynamic properties of meropenem. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  France Mentré,et al.  Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R , 2008, Comput. Methods Programs Biomed..

[36]  Jerome J. Schentag,et al.  Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid , 2007, Antimicrobial Agents and Chemotherapy.

[37]  C. Roussos,et al.  Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa , 2007, Intensive Care Medicine.

[38]  D. Nicolau,et al.  Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections , 2007, Antimicrobial Agents and Chemotherapy.

[39]  D. Breilh,et al.  Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia , 2006, Intensive Care Medicine.

[40]  J. Golden,et al.  Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. , 2005, International journal of antimicrobial agents.

[41]  Vincent H. Tam,et al.  Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.

[42]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[43]  M. Nishimura,et al.  Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. , 2003, American journal of respiratory and critical care medicine.

[44]  G. Amsden,et al.  Intrapulmonary Pharmacokinetics of Antibacterial Agents , 2002, American journal of respiratory medicine : drugs, devices, and other interventions.

[45]  J. Mouton.  International Society of Anti-infective Pharmacology , 2002 .

[46]  B. Allegranzi,et al.  Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid. , 2000, The Journal of antimicrobial chemotherapy.

[47]  P. Dargaville,et al.  Validity of markers of dilution in small volume lung lavage. , 1999, American journal of respiratory and critical care medicine.

[48]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[49]  J. Rello,et al.  Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment E cacy in Future Hospital- acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials , 2019 .

[50]  J. Rello,et al.  Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. , 2016, The Journal of antimicrobial chemotherapy.

[51]  B. Lambermont,et al.  Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. , 2015, The Journal of antimicrobial chemotherapy.

[52]  A. Mancini,et al.  Validation of a severity of illness score (APACHE II) in a surgical intensive care unit , 2004, Intensive Care Medicine.

[53]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[54]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[55]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.